GI bleeding more common with rivaroxaban than other direct oral anticoagulants

GI bleeding more common with rivaroxaban than other direct oral anticoagulants

Rivaroxaban appeared associated with a higher rate of gastrointestinal bleeding than other direct oral anticoagulants, according to study results published in Annals of Internal Medicine.Patients treated with rivaroxaban (Xarelto, Janssen) demonstrated a 40% higher overall risk for GI bleeding and a 50% higher risk for major GI bleeding than those treated with apixaban (Eliquis; Bristol Myers Squibb, Pfizer).“[The findings of this study] may help guide oral anticoagulant selection, especially for patients at high risk for GI bleeding,” Einar S. Björnsson, MD, PhD, professorRead More

Share on facebook
Share on twitter
Share on linkedin